Article abstract


Nature Medicine 15, 766 - 773 (2009)
Published online: 28 June 2009 | doi:10.1038/nm.1984

Targeted depletion of lymphotoxin-alpha–expressing TH1 and TH17 cells inhibits autoimmune disease

Eugene Y Chiang1,5, Ganesh A Kolumam1,5, Xin Yu1, Michelle Francesco1, Sinisa Ivelja1, Ivan Peng1, Peter Gribling1, Jean Shu1, Wyne P Lee1, Canio J Refino1, Mercedesz Balazs1, Andres Paler-Martinez1, Allen Nguyen2, Judy Young2, Kai H Barck3, Richard A D Carano3, Ron Ferrando4, Lauri Diehl4, Devavani Chatterjea1 & Jane L Grogan1


Uncontrolled T helper type 1 (TH1) and TH17 cells are associated with autoimmune responses. We identify surface lymphotoxin-alpha (LT-alpha) as common to TH0, TH1 and TH17 cells and employ a unique strategy to target these subsets using a depleting monoclonal antibody (mAb) directed to surface LT-alpha. Depleting LT-alpha–specific mAb inhibited T cell–mediated models of delayed-type hypersensitivity and experimental autoimmune encephalomyelitis. In collagen-induced arthritis (CIA), preventive and therapeutic administration of LT-alpha–specific mAb inhibited disease, and immunoablated T cells expressing interleukin-17 (IL-17), interferon-gamma and tumor necrosis factor-alpha (TNF-alpha), whereas decoy lymphotoxin-beta receptor (LT-betaR) fusion protein had no effect. A mutation in the Fc tail, rendering the antibody incapable of Fcgamma receptor binding and antibody-dependent cellular cytotoxicity activity, abolished all in vivo effects. Efficacy in CIA was preceded by a loss of rheumatoid-associated cytokines IL-6, IL-1beta and TNF-alpha within joints. These data indicate that depleting LT-alpha–expressing lymphocytes with LT-alpha–specific mAb may be beneficial in the treatment of autoimmune disease.

Top
  1. Departments of Immunology, South San Francisco, California, USA.
  2. Assay and Automation Technology, South San Francisco, California, USA.
  3. Tumor Biology and Angiogenesis, South San Francisco, California, USA.
  4. Pathology, Genentech, Inc., South San Francisco, California, USA.
  5. These authors contributed equally to this work.

Correspondence to: Jane L Grogan1 e-mail: jgrogan@gene.com



MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Targeting lymphotoxin depletes pathogenic T cells

Nature Medicine News and Views (01 Jul 2009)


Extra navigation

Subscribe to Nature Medicine

Subscribe

Open Innovation Challenges

naturejobs

ADVERTISEMENT